Tirofiban Administration in Acute Ischemic Stroke Treatments

Tirofiban, a reversible glycoprotein IIb/IIIa inhibitor, is increasingly used as adjunctive therapy in acute ischaemic stroke to prevent platelet aggregation during and after reperfusion interventions. Clinical strategies have explored systemic intravenous regimens following mechanical thrombectomy as well as targeted intra-arterial delivery alongside stent deployment. Retrospective analyses suggest that an effective response to tirofiban correlates with improved 90-day functional outcomes, and that longer infusion durations may further benefit neurological recovery without substantially increasing intracerebral haemorrhage risk. Trials in patients ineligible for early recanalisation highlight potential gains in disability reduction when tirofiban is administered within 12 hours of symptom onset. Diverse dosing protocols, ranging from low-dose intra-arterial boluses to standard intravenous administrations, have been assessed, demonstrating favourable recanalisation rates and acceptable safety profiles across large artery atherosclerosis and general stroke populations. However, the impact of stroke aetiology on efficacy, optimal administration route, and balancing haemorrhagic risk remain active areas of investigation. Emerging evidence emphasises tailored approaches, integrating patient-specific factors such as baseline stroke severity, vascular anatomy and recanalisation status, to maximise therapeutic benefit.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Tirofiban Administration in Acute Ischemic Stroke Treatments publication trend

The graph below shows the total number of articles in tirofiban administration in acute ischemic stroke treatments across all publications each year (not limited to Nature Index journals).

Technical terms

Acute ischaemic stroke (AIS): Sudden loss of blood supply to a brain region due to arterial occlusion.

Endovascular treatment (EVT): Minimally invasive procedures to restore vessel patency, including mechanical thrombectomy.

NIHSS (National Institutes of Health Stroke Scale): Standardised scale to assess neurological deficits in stroke patients.

Modified Rankin Scale (mRS): Six-point scale measuring degree of disability or dependence after stroke.

Symptomatic intracerebral haemorrhage (sICH): Clinically significant bleeding within the brain associated with neurological deterioration.

Modified Thrombolysis in Cerebral Infarction (mTICI) score: Angiographic grading of reperfusion success after endovascular therapy.

Intra-arterial (IA) and Intravenous (IV): Routes of drug administration, directly into an artery versus into a vein.

Glycoprotein IIb/IIIa inhibitor: Class of antiplatelet agents that block the final common pathway of platelet aggregation.

Recanalisation: Restoration of blood flow through a previously occluded cerebral artery.

References

1. Factors affecting the outcomes of tirofiban after endovascular treatment in acute ischemic stroke: Experience from a single center. CNS Neuroscience & Therapeutics (2023).
2. Safety and efficacy of different tirofiban administration routes on acute ischemic stroke patients with successful recanalization: A propensity score matching analysis. CNS Neuroscience & Therapeutics (2022).
3. Intravenous Administration of Standard Dose Tirofiban after Mechanical Arterial Recanalization is Safe and Relatively Effective in Acute Ischemic Stroke. Aging and Disease (2019).
4. Safety of bridging antiplatelet therapy with the gpIIb-IIIa inhibitor tirofiban after emergency stenting in stroke. PLOS ONE (2017).
5. Safety and Efficacy of Tirofiban Combined With Mechanical Thrombectomy Depend on Ischemic Stroke Etiology. Frontiers in Neurology (2019).
6. Safety and Efficacy of Tirofiban for Acute Ischemic Stroke Patients With Large Artery Atherosclerosis Stroke Etiology Undergoing Endovascular Therapy. Frontiers in Neurology (2021).